Plain-English translation of NCT06290193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a technique called acute normovolemic hemodilution (ANH) to see if it can help reduce the need for blood transfusions during major cancer surgery. ANH works by removing some of your own blood before surgery begins, which makes your remaining blood thinner and may reduce bleeding during the operation. Researchers believe this approach could keep more patients from needing donated blood during their cytoreductive surgery for advanced ovarian, fallopian tube, or peritoneal cancer.
Major cancer surgery can cause significant blood loss, and many patients need transfusions from blood donors. This trial exists because doctors want to find ways to reduce the need for donated blood transfusions, which carries small risks and may not always be available when needed.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive the new blood-thinning technique during your surgery or to receive standard surgical care. Your surgery itself will happen as planned, but the way doctors manage your blood during the operation may differ based on which group you're in. Researchers will track how much blood you lose, whether you need a transfusion, and how you recover after surgery.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States